Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Immunol Res ; 2022: 9962397, 2022.
Article in English | MEDLINE | ID: mdl-35915657

ABSTRACT

Although tumor immune microenvironment plays an important role in antitumor therapy, few studies explored the gene signatures associated with the tumor immune microenvironment of bladder cancer after neoadjuvant chemotherapy. We examined and analyzed differentially expressed genes from 9 patients with stage I-III bladder cancer by RNA immune-oncology profiling platform. After neoadjuvant chemotherapy, the expressions of 43 genes in 19 pathways and 10 genes in 5 pathways were upregulated and downregulated, respectively. Neoadjuvant chemotherapy also promoted the expression of genes related to the activation of antitumor immune responses and decreased the expression of genes related to tumor proliferation pathways. In addition, neoadjuvant chemotherapy improved tumor response to immune checkpoint blockade. Furthermore, this study also identified several genes that can be used to predict the efficacy of neoadjuvant chemotherapy and their possible molecular mechanisms. In conclusion, neoadjuvant chemotherapy may promote the activation of antitumor effects, improve the suppressive tumor immune microenvironment, and increase the sensitivity of bladder cancer to immune checkpoint blockade.


Subject(s)
Neoadjuvant Therapy , Urinary Bladder Neoplasms , Humans , Immune Checkpoint Inhibitors/pharmacology , Immune Checkpoint Inhibitors/therapeutic use , Tumor Microenvironment , Urinary Bladder Neoplasms/drug therapy , Urinary Bladder Neoplasms/genetics
2.
J Endourol ; 25(8): 1337-41, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21815794

ABSTRACT

PURPOSE: To report our preliminary techniques and experience with transumbilical laparoendoscopic single-site renal pedicle lymphatic disconnection (LESS-RPLD) in seven patients with refractory chyluria. PATIENTS AND METHODS: Between June 2009 and September 2010, seven patients with refractory chyluria underwent LESS-RPLD. In the patients, a 2- to 3-cm single inverted U-shaped supraumbilical incision was made, and a homemade single multichannel port using a surgical glove and three conventional trocars was placed into the abdominal cavity. Flexible electric coagulation hook and pliers were used for renal pedicle dissection. A straight ultrasound knife was used for lymphatic disconnection. RESULTS: All the operations were successfully completed without conversion to open surgery, although an additional 3-mm trocar was used to push the liver in one patient. The mean operative time was 125 (96-165) minutes. The mean blood loss was estimated to be 112 (50-250) mL. Chyluria disappeared in all patients after surgery and did not recur during the follow-up period (3-15, mean 8.3 mos). CONCLUSION: LESS-RPLD is safe and feasible, with favorable short-term outcomes and aesthetic effect.


Subject(s)
Chyle/metabolism , Digestive System Diseases/surgery , Kidney/surgery , Laparoscopy , Lymphatic Vessels/surgery , Umbilicus/surgery , Adult , Digestive System Diseases/diagnostic imaging , Digestive System Diseases/pathology , Female , Humans , Intraoperative Care , Kidney/diagnostic imaging , Kidney/pathology , Lymphatic Vessels/diagnostic imaging , Lymphatic Vessels/pathology , Male , Middle Aged , Postoperative Care , Umbilicus/diagnostic imaging , Umbilicus/pathology , Urine , Urography
SELECTION OF CITATIONS
SEARCH DETAIL
...